Related Experiment Videos
Percutaneous ethanol injection therapy for recurrent hepatocellular carcinoma
1Second Department of Medicine, Kurume University School of Medicine, Japan.
Hepato-Gastroenterology
|August 1, 1993
Summary
Regular ultrasound follow-up is crucial for patients with small hepatocellular carcinoma (HCC) treated with percutaneous ethanol injection therapy (PEIT). This monitoring detects recurrence, improving survival rates in this challenging liver cancer.
Area of Science:
- Hepatology
- Oncology
- Medical Imaging
Background:
- Small hepatocellular carcinoma (HCC) often presents in patients with chronic liver disease and cirrhosis.
- Multinodular lesions are common in HCC, limiting surgical resection efficacy.
- Percutaneous ethanol injection therapy (PEIT) is a treatment option for small HCC.
Purpose of the Study:
- To evaluate the efficacy of PEIT for small HCC.
- To assess the recurrence rate after PEIT.
- To determine the impact of regular follow-up on survival rates.
Main Methods:
- Follow-up study of 250 small HCC cases treated with PEIT.
- Regular ultrasonography (US) monitoring for tumor recurrence.
- Analysis of 5-year survival rates based on follow-up adherence.
Main Results:
- Recurrence was observed in 96.1% of small HCC cases post-PEIT.
- The 5-year survival rate for all treated cases was 46.7%.
- Patients not followed by regular US showed significantly poorer survival rates.
Conclusions:
- Regular US follow-up is essential for detecting HCC recurrence after PEIT.
- PEIT can achieve a 5-year survival rate of 46.7% with diligent monitoring.
- Developing strategies to prevent HCC recurrence is a critical future direction.